1. Home
  2. HSCS vs NXL Comparison

HSCS vs NXL Comparison

Compare HSCS & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heart Test Laboratories Inc.

HSCS

Heart Test Laboratories Inc.

HOLD

Current Price

$2.76

Market Cap

6.4M

Sector

Health Care

ML Signal

HOLD

Logo Nexalin Technology Inc.

NXL

Nexalin Technology Inc.

HOLD

Current Price

$0.33

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HSCS
NXL
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4M
7.5M
IPO Year
2022
2022

Fundamental Metrics

Financial Performance
Metric
HSCS
NXL
Price
$2.76
$0.33
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
62.2K
134.3K
Earning Date
03-16-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
50.84
39.76
EPS
N/A
N/A
Revenue
$4,319.00
$301,647.00
Revenue This Year
N/A
$15.52
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
78.78
52 Week Low
$1.63
$0.31
52 Week High
$3.80
$2.00

Technical Indicators

Market Signals
Indicator
HSCS
NXL
Relative Strength Index (RSI) 62.76 40.60
Support Level $2.61 $0.33
Resistance Level $2.76 $0.50
Average True Range (ATR) 0.22 0.03
MACD 0.07 -0.00
Stochastic Oscillator 82.99 8.33

Price Performance

Historical Comparison
HSCS
NXL

About HSCS Heart Test Laboratories Inc.

HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.

About NXL Nexalin Technology Inc.

Nexalin Technology Inc designs and develops neurostimulation products and bioelectronic medical technology to treat anxiety and insomnia without drugs or psychotherapy. The Company has developed the Generation 1 (Gen 1) medical device, a cranial electrotherapy stimulation (CES) device classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The Company operates as a single operating and reportable segment, focused on the design and development of innovative neurostimulation products. The Company focuses on treating mental health conditions without reliance on drugs or psychotherapy. Geographically, it generates sales in the USA and China, with China generating the maximum sales.

Share on Social Networks: